Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

YAP1 Mediates Resistance to MEK1/2 Inhibition in Neuroblastomas with Hyperactivated RAS Signaling.

Cancer research - 15 Dec 2019

Coggins Grace E, Farrel Alvin, Rathi Komal S, Hayes Colin M, Scolaro Laura, Rokita Jo Lynne, Maris John M

Abstract excerpt

Relapsed neuroblastomas are enriched with activating mutations of the RAS-MAPK signaling pathway. The MEK1/2 inhibitor trametinib delays tumor growth but does not sustain regression in neuroblastoma preclinical models. Recent studies have implicated the Hippo pathway transcriptional coactivator protein YAP1 as an additional driver of relapsed neuroblastomas, as well as a mediator of trametinib resistance in other...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adaptor Proteins, Signal Transducing
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to MAP Kinase Signaling System

Share to Neuroblastoma

Share to Proto-Oncogene Proteins p21(ras)

Share to Pyridones

Share to Pyrimidinones

Share to YAP-Signaling Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 31672841
DOI: 10.1158/0008-5472.CAN-19-1415
PMCID: PMC6911631

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

YAP1 Mediates Resistance to MEK1/2 Inhibition in Neuroblastomas with Hyperactivated RAS Signaling.PMID 31672841Read ↗

Yap1 Mediates Trametinib Resistance in Head and Neck Squamous Cell CarcinomasSemantic proximity Read ↗

The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies.Semantic proximity Read ↗

Efficacy of RMC-6236 (Daraxonrasib) and novel combination strategies targeting resistance in RAS pathway-driven neuroblastomaSemantic proximity Read ↗

Comprehensive analysis of TEAD inhibition in meningioma identifies MEK and mTOR inhibition as effective combination therapies against resistant linesSemantic proximity Read ↗

YAP signaling promotes resistance to MEK and AKT inhibition in <i>NF1</i> -related MPNSTsSemantic proximity Read ↗

YAP/TAZ Inhibition Induces Metabolic and Signaling Rewiring Resulting in Targetable Vulnerabilities in NF2-Deficient Tumor CellsSemantic proximity Read ↗

Hippo pathway effectors YAP1/TAZ induce a EWS-FLI1-opposing gene signature and associate with disease progression in Ewing SarcomaSemantic proximity Read ↗

SHP2 Inhibition with TNO155 Increases Efficacy and Overcomes Resistance of ALK Inhibitors in NeuroblastomaSemantic proximity Read ↗

Cross-Cohort Analysis Identifies a TEAD4–MYCN Positive Feedback Loop as the Core Regulatory Element of High-Risk NeuroblastomaSemantic proximity Read ↗

Understanding and overcoming innate and acquired MAPK-inhibition resistance in anaplastic thyroid cancerSemantic proximity Read ↗

Transcription factor activating protein 4 is synthetically lethal and a master regulator of MYCN-amplified neuroblastomaSemantic proximity Read ↗

NRAS Status Determines Sensitivity to SHP2 Inhibitor Combination Therapies Targeting the RAS-MAPK Pathway in Neuroblastoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.